What to Do When First-Line Migraine Prevention Fails in Frequent or Severe Migraine with Brainstem Aura

This protocol applies to patients with migraine with brainstem aura who have received first-line preventive therapy but have not yet achieved a meaningful reduction in attack frequency.

Clinical Scenario

Prevention is warranted — and this next-line step becomes relevant — when any of the following apply:

Three or more migraine attacks per month with negative impact on quality of life
Migraine attacks that regularly last longer than 72 hours
Migraine with persistent aura
Attacks that are unresponsive to acute therapy

Previous Treatment Line & Reason for Escalation

First-line prevention — target not met

The preceding step comprised drug prevention with high-evidence substances given in slowly increasing doses: beta blockers Propranolol, Metoprolol, or Bisoprolol; the calcium antagonist Flunarizine; Valproic acid; Topiramate; or Amitriptyline — and, in chronic migraine, OnabotulinumtoxinA.

The target for that step: a reduction of migraine attack frequency by 50% or more, evaluated two months after reaching the highest tolerated dose. This protocol is the structured next step when that goal was not achieved.

Next-Line Approach (overview — partial)

The full protocol at this step involves either switching to a preventive agent with a different evidence profile or introducing a combination therapy approach. Which option and the precise selection logic are specified in the complete regimen.

Treatment Target

Goal: reduction of migraine attack frequency by 50% or more.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1177/2514183X1882337

In frequent migraine attacks or migraine patients with severe symptoms or persistent aura, migraine prevention should be offered in addition to prevention by education and behavioural therapy.

If no improvement in migraine frequency is achieved within two months after the targeted or tolerated final dose, a switch should be made to a different substance.

If there is no or only inadequate response to a monotherapy, combination therapy may be considered.

Migraine prevention is considered effective when it achieves a reduction of the migraine attack frequency of 50% or more.

View source ↗